Rapid test for fecal calprotectin levels in children with Crohn disease

K. L. Kolho*, D. Turner, G. Veereman-Wauters, M. Sladek, L. De Ridder, R. Shaoul, A. Paerregaard, J. Amil Dias, S. Koletzko, F. Nuti, Y. Bujanover, A. Staiano, K. Bochenek, L. Finnby, A. Levine, G. Veres

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

38 Scopus citations


Assessment of fecal calprotectin, a surrogate marker of mucosal inflammation, is a promising means to monitor therapeutic response in pediatric inflammatory bowel disease, especially if the result is readily available. We tested the performance of a novel calprotectin rapid test, Quantum Blue, versus the conventional enzyme-linked immunosorbent assay in 134 stool samples from 56 pediatric patients with Crohn disease. The intraclass correlation coefficient analysis reflected good agreement (intraclass correlation coefficient 0.97 [95% confidence interval 0.95-0.98]) but agreement was better in lower values, where dilutions were not required. Using a cutoff of 100μg/g for normal values, the percentage agreement between the 2 tests was 87%. The optimal cutoff values to guide clinical decisions in the therapy of inflammatory bowel disease have yet to be determined.

Original languageAmerican English
Pages (from-to)436-439
Number of pages4
JournalJournal of Pediatric Gastroenterology and Nutrition
Issue number4
StatePublished - Oct 2012


  • Fecal biomarkers
  • Inflammatory bowel disease
  • Pediatric


Dive into the research topics of 'Rapid test for fecal calprotectin levels in children with Crohn disease'. Together they form a unique fingerprint.

Cite this